Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents

References

• Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med 2001; 344:1378-88; PMID:11333996; http://dx.doi.org/10.1056/NEJM200105033441807
   PubMed Web of Science ®Google Scholar
• Thompson MJ, Ninis N, Perera R, Mayon-White R, Phillips C, Bailey L, Harnden A, Mant D, Levin M. Clinical recognition of meningococcal disease in children and adolescents. Lancet 2006; 367:397-403; PMID:16458763; http://dx.doi.org/10.1016/S0140-6736(06)67932-4
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, Baker CJ, Messonnier NE; Centers for Disease Control and Prevention. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Motal Wkly Rep 2013; 62:1-28.
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, Schmidt M, Pondo T, Arnold KE, Baumbach J, Bennett N, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998–2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010; 50:184-91; PMID:20001736; http://dx.doi.org/10.1086/649209
   PubMed Web of Science ®Google Scholar
• World Health Organization. Meningococcal vaccines: WHO position paper, November 2011. Weekly Epidemiol Rec. 2011; 86:521-39; PMID:22128384
   PubMedGoogle Scholar
• Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009; 27:B51-63; PMID:19477562; http://dx.doi.org/10.1016/j.vaccine.2009.04.063
   PubMed Web of Science ®Google Scholar
• Keyserling H, Pollard AJ, DeTora LM, Gilmet GP. Experience with MCV-4, a meningococcal, diphtheria toxoid conjugate vaccine against serogroups A, C, Y and W-135. Expert Rev Vaccines 2006; 5:445-59; PMID:16989625; http://dx.doi.org/10.1586/14760584.5.4.445
   PubMed Web of Science ®Google Scholar
• Croxtall JD, Dhillon S. Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix). Drugs 2012; 72:2407-30; PMID:23231026; http://dx.doi.org/10.2165/11209580-000000000-00000
   PubMed Web of Science ®Google Scholar
• Broker M, Cooper B, Detora LM, Stoddard JJ. Critical appraisal of a quadrivalent CRM(197) conjugate vaccine against meningococcal serogroups A, C W-135 and Y (Menveo) in the context of treatment and prevention of invasive disease. Infect Drug Resist 2011; 4:137-47; PMID:21904459; http://dx.doi.org/10.2147/IDR.S12716
   PubMedGoogle Scholar
• Kelly DF, Snape MD, Clutterbuck EA, Green S, Snowden C, Diggle L, Yu LM, Borkowski A, Moxon ER, Pollard AJ. CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells. Blood 2006; 108:2642-7; PMID:16675705; http://dx.doi.org/10.1182/blood-2006-01-009282
   PubMed Web of Science ®Google Scholar
• Trotter CL, Maiden MC. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines 2009; 8:851-61; http://dx.doi.org/10.1586/erv.09.48
   PubMed Web of Science ®Google Scholar
• Daugla D, Gami J, Gamougam K, Naibei N, Mbainadji L, Narbe M, Toralta J, Kodbesse B, Ngadoua C, Coldiron M, et al. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community trial. Lancet 2014; 383:40-7; PMID:24035220; http://dx.doi.org/10.1016/S0140-6736(13)61612-8
   PubMed Web of Science ®Google Scholar
• Read RC, Baxter D, Chadwick DR, Faust SN, Finn A, Gordon SB, Heath PT, Lewis DJM, Pollard AJ, Turner DPJ et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet 2014; 384:2123-31; PMID:25145775; http://dx.doi.org/10.1016/S0140-6736(14)60842-4
   PubMed Web of Science ®Google Scholar
• Snape MD, Perrett KP, Ford KJ, John TM, Pace D, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 2008; 299:173-84; PMID:18182599; http://dx.doi.org/10.1001/jama.2007.29-c
   PubMed Web of Science ®Google Scholar
• Jackson LA, Baxter R, Reisinger K, Karsten A, Shah J, Bedell L, Dull PM; V59P13 Study Group. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Clin Infect Dis 2009; 49:e1-10; PMID:19476428; http://dx.doi.org/10.1086/599117
   PubMed Web of Science ®Google Scholar
• Stamboulian D, Lopardo G, Lopez P, Cortes-Barbosa C, Valencia A, Bedell L, Karsten A, Dull PM. Safety and immunogenicity of an investigational quadrivalent meningococcal CRM197 conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America. Int J Infect Dis 2010; 14:e868-75; PMID:20655261; http://dx.doi.org/10.1016/j.ijid.2010.03.017
   PubMed Web of Science ®Google Scholar
• Finne J, Bitter-Suermann D, Goridis C, Finne U. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol 1987; 138:4402-7; PMID:3108388
   PubMed Web of Science ®Google Scholar
• Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med 2010; 362:1511-20; PMID:20410516; http://dx.doi.org/10.1056/NEJMra0906357
   PubMed Web of Science ®Google Scholar
• Pizza M, Scarlato V, Masignani V, Giuliani MM, Arico B, Comanducci M, Jennings GT, Baldi L, Bartolini E, Capecchi B, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000; 287:1816-20; PMID:10710308; http://dx.doi.org/10.1126/science.287.5459.1816
   PubMed Web of Science ®Google Scholar
• Giuliani MM, Adu-Bobie J, Comanducci M, Aricò B, Savino S, Santini L, Brunelli B, Bambini S, Biolchi A, Capecchi B, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Scie U S A 2006; 103: 10834-39; http://dx.doi.org/10.1073/pnas.0603940103
   PubMed Web of Science ®Google Scholar
• Snape MD, Dawson T, Oster P, Evans A, John TM, Ohene-Kena B, Findlow J, Yu LM, Borrow R, Ypma E, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Disease J 2010; 29:e71-9; http://dx.doi.org/10.1097/INF.0b013e3181b0602e
   Web of Science ®Google Scholar
• Findlow J, Borrow R, Snape MD, Dawson T, Holland A, John TM, Evans A, Telford KL, Ypma E, Toneatto D, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010; 51:1127-37; PMID:20954968; http://dx.doi.org/10.1086/656741
   PubMed Web of Science ®Google Scholar
• Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S, Principi N, Diez-Domingo J, Sokal E, Becker B, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012; 307:573-82; PMID:22318278; http://dx.doi.org/10.1001/jama.2012.85
   PubMed Web of Science ®Google Scholar
• Kimura A, Toneatto D, Kleinschmidt A, Wang H, Dull P. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin Vaccine Immunol 2011; 18:483-6; PMID:21177912; http://dx.doi.org/10.1128/CVI.00304-10
   PubMed Web of Science ®Google Scholar
• Santolaya ME, O'Ryan ML, Valenzuela MT, Prado V, Vergara R, Munoz A, Toneatto D, Grana G, Wang H, Clemens R, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012; 379:617-24; PMID:22260988; http://dx.doi.org/10.1016/S0140-6736(11)61713-3
   PubMed Web of Science ®Google Scholar
• Vesikari T, Esposito S, Prymula R, Ypma E, Kohl I, Toneatto D, Dull P, Kimura A; EU Meningococcal B Infant Vaccine Study group. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet 2013; 381:825-35; PMID:23324563; http://dx.doi.org/10.1016/S0140-6736(12)61961-8
   PubMed Web of Science ®Google Scholar
• Racloz VN, Luiz SJ. The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology. BMC Infect Dis 2010;10:175; PMID:20565757; http://dx.doi.org/10.1186/1471-2334-10-175
   PubMed Web of Science ®Google Scholar
• Beernink PT, Caugant DA, Welsch JA, Koeberling O, Granoff DM. Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa. J Infect Dis 2009; 199(9):1360-8; PMID:19302008; http://dx.doi.org/10.1086/597806
   PubMed Web of Science ®Google Scholar
• Pajon R, Fergus AM, Koeberling O, Caugant DA, Granoff DM. Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development. PLoS Negl Trop Dis 2011; 5:e1302; PMID:21909444; http://dx.doi.org/10.1371/journal.pntd.0001302
   PubMedGoogle Scholar
• Hong E, Giuliani MM, Deghmane AE, Comanducci M, Brunelli B, Dull P, Pizza M, Taha MK. Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa? Vaccine 2013; 31:1113-6; PMID:23261039; http://dx.doi.org/10.1016/j.vaccine.2012.12.022
   PubMed Web of Science ®Google Scholar
• Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, Moxon ER, Stella M, Comanducci M, Bambini S, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA 2010; 107:19490-95; http://dx.doi.org/10.1073/pnas.1013758107
   PubMed Web of Science ®Google Scholar
• Holst J, Martin D, Arnold R, Huergo CC, Oster P, O'Hallahan J, Rosenqvist E. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009; 27:B3-12; PMID:19481313; http://dx.doi.org/10.1016/j.vaccine.2009.04.071
   PubMed Web of Science ®Google Scholar
• Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 2009; 27S:B112-16; http://dx.doi.org/10.1016/j.vaccine.2009.04.065
   Google Scholar
• Mak PA, Santos GF, Masterman K-A, Janes J, Wacknov B, Vienken K, Giuliani M, Herman AE, Cooke M, Mbow ML, et al. Development of an automated, high-throughput bactericidal assay that measures cellular respiration as a survival readout for Neisseria meningitidis. Clin Vaccine Immunol 2011; 18:1252-60; PMID:21715580; http://dx.doi.org/10.1128/CVI.05028-11
   PubMed Web of Science ®Google Scholar